353:
InChI=1S/C143H244N50O42S4/c1-13-76(10)112-137(232)189-99(68-199)131(226)188-98(67-198)130(225)187-97(66-197)129(224)186-96(65-196)117(212)166-59-105(202)169-90(52-72(2)3)114(209)163-61-107(204)171-100(132(227)177-83(32-19-22-44-146)124(219)190-111(75(8)9)136(231)184-91(53-73(4)5)127(222)175-84(34-24-46-159-141(151)152)121(216)174-85(35-25-47-160-142(153)154)122(217)185-94(139(234)235)55-78-57-157-71-167-78)69-238-239-70-101(172-108(205)62-165-116(211)95(64-195)170-106(203)60-162-113(208)87(38-39-103(148)200)181-135(230)110(74(6)7)191-126(221)89(41-51-237-12)179-120(215)82(31-18-21-43-145)180-134(229)102-37-27-49-193(102)138(233)79(147)63-194)133(228)182-92(54-77-28-15-14-16-29-77)115(210)164-58-104(201)168-80(33-23-45-158-140(149)150)118(213)173-81(30-17-20-42-144)119(214)178-88(40-50-236-11)123(218)183-93(56-109(206)207)128(223)176-86(125(220)192-112)36-26-48-161-143(155)156/h14-16,28-29,57,71-76,79-102,110-112,194-199H,13,17-27,30-56,58-70,144-147H2,1-12H3,(H2,148,200)(H,157,167)(H,162,208)(H,163,209)(H,164,210)(H,165,211)(H,166,212)(H,168,201)(H,169,202)(H,170,203)(H,171,204)(H,172,205)(H,173,213)(H,174,216)(H,175,222)(H,176,223)(H,177,227)(H,178,214)(H,179,215)(H,180,229)(H,181,230)(H,182,228)(H,183,218)(H,184,231)(H,185,217)(H,186,224)(H,187,225)(H,188,226)(H,189,232)(H,190,219)(H,191,221)(H,192,220)(H,206,207)(H,234,235)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)/t76-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,110-,111-,112-/m0/s1
311:
333:
CC(C)1C(=O)N(C(=O)N(C(=O)N(C(=O)N(C(=O)NCC(=O)N(C(=O)NCC(=O)N(CSSC(C(=O)N(C(=O)NCC(=O)N(C(=O)N(C(=O)N(C(=O)N(C(=O)N(C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)(CO)NC(=O)CNC(=O)(CCC(=O)N)NC(=O)(C(C)C)NC(=O)(CCSC)NC(=O)(CCCCN)NC(=O)3CCCN3C(=O)(CO)N)C(=O)N(CCCCN)C(=O)N(C(C)C)C(=O)N(CC(C)C)C(=O)N(CCCNC(=N)N)C(=O)N(CCCNC(=N)N)C(=O)N(CC4=CNC=N4)C(=O)O)CC(C)C)CO)CO)CO)CO
42:
674:
Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K (April 2005). "Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials".
1013:
880:
819:
910:
84:
1006:
485:
convened a panel of experts whose advice included the recommendation to conduct the large-scale clinical trial that was subsequently published in 2011. Following this, the
1290:
369:
788:
850:
1295:
754:
474:
on the efficacy and side effects of nesiritide, Johnson & Johnson met with the FDA and altered its stated plans for the drug and agreed to revise its labeling.
999:
609:
410:
54:
325:
872:
710:
Aaronson KD, Sackner-Bernstein J (September 2006). "Risk of death associated with nesiritide in patients with acutely decompensated heart failure".
811:
462:/kg followed by a continuous IV infusion of 0.01 mg/kg/min. This may be increased every three hours for a maximum of 0.03 mg/kg/min.
1241:
902:
432:
for this purpose in 2001 after initial non-approval. In July 2011, the results of the largest study so far for nesiritide was published in
486:
434:
425:
345:
780:
842:
414:
746:
1084:
1047:
429:
199:
1258:
471:
398:
1246:
568:
438:. The study failed to show a difference between nesiritide and placebo on mortality or re-hospitalizations.
72:
1059:
567:
O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. (July 2011).
489:
announced an inquiry into the marketing of the drug that led to a fine against the Scios unit of J&J.
418:
228:
635:"Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure"
986:
1053:
482:
114:
873:"Johnson & Johnson Subsidiary Scios Pleads Guilty to Misbranding Heart Failure Drug Natrecor"
991:
1285:
967:
727:
692:
656:
601:
188:
1064:
1039:
957:
949:
719:
684:
646:
591:
583:
532:
478:
451:
244:
123:
401:, which is normally produced by the ventricular myocardium. Nesiritide works to facilitate
208:
1089:
1026:
394:
1252:
962:
937:
651:
634:
402:
1279:
522:
148:
1187:
1132:
1030:
481:
then voted unanimously not to permit the prescription of the drug to its patients.
97:
92:
64:
953:
1212:
1177:
1137:
1116:
1097:
1074:
1069:
1022:
537:
517:
501:
447:
406:
1227:
1207:
1202:
1197:
1172:
1167:
1147:
1079:
542:
283:
179:
723:
688:
1217:
1182:
1162:
1142:
1107:
459:
58:
971:
731:
696:
660:
605:
33:
587:
1222:
1157:
569:"Effect of nesiritide in patients with acute decompensated heart failure"
507:
159:
168:
17:
1152:
936:
Noviasky JA, Kelberman M, Whalen KM, Guharoy R, Darko W (August 2003).
596:
455:
134:
41:
547:
512:
219:
310:
301:
995:
938:"Science or fiction: use of nesiritide as a first-line agent?"
633:
Sackner-Bernstein JD, Skopicki HA, Aaronson KD (March 2005).
424:
Nesiritide was believed initially to be beneficial for
376:
843:"U.S. Looking at Marketing by Johnson & Johnson"
470:
In 2005, after several academic papers published by
1125:
1106:
1038:
454:, followed by IV infusion. For most adults and the
299:
282:
243:
238:
218:
198:
178:
158:
133:
113:
108:
83:
71:
53:
48:
147:
903:"Natrecor Adverse Reactions - Epocrates Online"
781:"Heart Clinic May End or Curtail Use of a Drug"
428:. It received approval from the United States'
122:
1007:
8:
426:acute decompensated congestive heart failure
32:
1014:
1000:
992:
187:
1291:Drugs acting on the cardiovascular system
961:
650:
595:
207:
1296:Drugs developed by Johnson & Johnson
812:"Bitter Pill For J&J On Heart Drug"
747:"The Marketing and Success of Natrecor"
559:
350:
330:
167:
774:
772:
31:
757:from the original on 4 September 2021
227:
63:
7:
411:renin–angiotensin–aldosterone system
96:
576:The New England Journal of Medicine
487:United States Department of Justice
435:The New England Journal of Medicine
138:
853:from the original on 23 March 2021
652:10.1161/01.CIR.0000159340.93220.E4
25:
883:from the original on 12 June 2021
409:through counterregulation of the
822:from the original on 17 May 2022
791:from the original on 4 June 2019
528:More rare side effects include:
446:Nesiritide is only administered
397:form of the 32 amino acid human
261:
255:
40:
913:from the original on 2020-03-08
615:from the original on 2021-02-11
358:Key:HPNRHPKXQZSDFX-OAQDCNSJSA-N
415:cyclic guanosine monophosphate
273:
267:
249:
1:
497:Common side effects include:
1085:Pentaerythritol tetranitrate
954:10.1592/phco.23.8.1081.32882
458:, a normal dosage is 2
430:Food and Drug Administration
389:, sold under the brand name
1312:
472:Jonathan Sackner-Bernstein
399:B-type natriuretic peptide
239:Chemical and physical data
1236:
810:Herper M (14 June 2005).
366:
341:
321:
39:
861:– via NYTimes.com.
799:– via NYTimes.com.
765:– via NYTimes.com.
724:10.1001/jama.296.12.1465
689:10.1001/jama.293.15.1900
841:Saul S (21 July 2005).
1060:Isosorbide mononitrate
745:Saul S (17 May 2005).
477:Heart doctors at the
779:Saul S (4 May 2005).
588:10.1056/NEJMoa1100171
1054:Isosorbide dinitrate
907:online.epocrates.com
483:Johnson and Johnson
36:
27:Pharmaceutical drug
1263:Never to phase III
879:. 5 October 2011.
847:The New York Times
785:The New York Times
751:The New York Times
502:Low blood pressure
1273:
1272:
1040:Nitrovasodilators
504:(11% of patients)
421:cell relaxation.
384:
383:
312:Interactive image
16:(Redirected from
1303:
1065:Itramin tosilate
1027:cardiac diseases
1016:
1009:
1002:
993:
975:
965:
922:
921:
919:
918:
899:
893:
892:
890:
888:
869:
863:
862:
860:
858:
838:
832:
831:
829:
827:
807:
801:
800:
798:
796:
776:
767:
766:
764:
762:
742:
736:
735:
707:
701:
700:
671:
665:
664:
654:
630:
624:
623:
621:
620:
614:
599:
573:
564:
479:Cleveland Clinic
380:
379:
372:
314:
294:
292:
275:
269:
263:
257:
251:
231:
211:
191:
171:
151:
141:
140:
126:
100:
67:
44:
37:
35:
21:
1311:
1310:
1306:
1305:
1304:
1302:
1301:
1300:
1276:
1275:
1274:
1269:
1268:
1253:Clinical trials
1232:
1121:
1102:
1090:Propatylnitrate
1034:
1020:
983:
978:
942:Pharmacotherapy
935:
931:
929:Further reading
926:
925:
916:
914:
901:
900:
896:
886:
884:
877:www.justice.gov
871:
870:
866:
856:
854:
840:
839:
835:
825:
823:
809:
808:
804:
794:
792:
778:
777:
770:
760:
758:
744:
743:
739:
709:
708:
704:
673:
672:
668:
645:(12): 1487–91.
632:
631:
627:
618:
616:
612:
571:
566:
565:
561:
556:
518:Slow heart rate
495:
468:
444:
375:
373:
370:(what is this?)
367:
362:
359:
354:
349:
348:
337:
334:
329:
328:
317:
290:
288:
278:
272:
266:
260:
254:
234:
214:
194:
174:
154:
137:
129:
104:
74:
28:
23:
22:
15:
12:
11:
5:
1309:
1307:
1299:
1298:
1293:
1288:
1278:
1277:
1271:
1270:
1267:
1266:
1265:
1264:
1261:
1250:
1244:
1238:
1237:
1234:
1233:
1231:
1230:
1225:
1220:
1215:
1210:
1205:
1200:
1195:
1190:
1185:
1180:
1175:
1170:
1165:
1160:
1155:
1150:
1145:
1140:
1135:
1129:
1127:
1123:
1122:
1120:
1119:
1113:
1111:
1104:
1103:
1101:
1100:
1095:
1092:
1087:
1082:
1077:
1072:
1067:
1062:
1057:
1051:
1044:
1042:
1036:
1035:
1021:
1019:
1018:
1011:
1004:
996:
990:
989:
982:
981:External links
979:
977:
976:
932:
930:
927:
924:
923:
894:
864:
833:
802:
768:
737:
718:(12): 1465–6.
702:
683:(15): 1900–5.
666:
625:
558:
557:
555:
552:
551:
550:
545:
540:
535:
526:
525:
523:Kidney failure
520:
515:
510:
505:
494:
491:
467:
464:
443:
442:Administration
440:
413:, stimulating
403:cardiovascular
382:
381:
364:
363:
361:
360:
357:
355:
352:
344:
343:
342:
339:
338:
336:
335:
332:
324:
323:
322:
319:
318:
316:
315:
307:
305:
297:
296:
286:
280:
279:
276:
270:
264:
258:
252:
247:
241:
240:
236:
235:
233:
232:
224:
222:
216:
215:
213:
212:
204:
202:
196:
195:
193:
192:
184:
182:
176:
175:
173:
172:
164:
162:
156:
155:
153:
152:
144:
142:
131:
130:
128:
127:
119:
117:
111:
110:
106:
105:
103:
102:
89:
87:
81:
80:
77:
75:administration
69:
68:
61:
51:
50:
46:
45:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
1308:
1297:
1294:
1292:
1289:
1287:
1284:
1283:
1281:
1262:
1260:
1257:
1256:
1254:
1251:
1248:
1245:
1243:
1240:
1239:
1235:
1229:
1226:
1224:
1221:
1219:
1216:
1214:
1211:
1209:
1206:
1204:
1201:
1199:
1196:
1194:
1191:
1189:
1186:
1184:
1181:
1179:
1176:
1174:
1171:
1169:
1166:
1164:
1161:
1159:
1156:
1154:
1151:
1149:
1146:
1144:
1141:
1139:
1136:
1134:
1131:
1130:
1128:
1124:
1118:
1115:
1114:
1112:
1109:
1105:
1099:
1096:
1093:
1091:
1088:
1086:
1083:
1081:
1078:
1076:
1073:
1071:
1068:
1066:
1063:
1061:
1058:
1055:
1052:
1049:
1048:Nitroglycerin
1046:
1045:
1043:
1041:
1037:
1032:
1028:
1024:
1017:
1012:
1010:
1005:
1003:
998:
997:
994:
988:
985:
984:
980:
973:
969:
964:
959:
955:
951:
948:(8): 1081–3.
947:
943:
939:
934:
933:
928:
912:
908:
904:
898:
895:
882:
878:
874:
868:
865:
852:
848:
844:
837:
834:
821:
817:
813:
806:
803:
790:
786:
782:
775:
773:
769:
756:
752:
748:
741:
738:
733:
729:
725:
721:
717:
713:
706:
703:
698:
694:
690:
686:
682:
678:
670:
667:
662:
658:
653:
648:
644:
640:
636:
629:
626:
611:
607:
603:
598:
593:
589:
585:
581:
577:
570:
563:
560:
553:
549:
546:
544:
541:
539:
536:
534:
531:
530:
529:
524:
521:
519:
516:
514:
511:
509:
506:
503:
500:
499:
498:
492:
490:
488:
484:
480:
475:
473:
465:
463:
461:
457:
453:
450:, usually by
449:
448:intravenously
441:
439:
437:
436:
431:
427:
422:
420:
419:smooth muscle
417:, leading to
416:
412:
408:
404:
400:
396:
392:
388:
378:
371:
365:
356:
351:
347:
340:
331:
327:
320:
313:
309:
308:
306:
303:
298:
287:
285:
281:
248:
246:
242:
237:
230:
229:ChEMBL1201668
226:
225:
223:
221:
217:
210:
206:
205:
203:
201:
197:
190:
186:
185:
183:
181:
177:
170:
166:
165:
163:
161:
157:
150:
146:
145:
143:
136:
132:
125:
121:
120:
118:
116:
112:
107:
99:
94:
91:
90:
88:
86:
82:
78:
76:
70:
66:
62:
60:
56:
52:
49:Clinical data
47:
43:
38:
30:
19:
1192:
1188:Levosimendan
1133:Benziodarone
1110:vasodilators
1023:Vasodilators
987:Natrecor.com
945:
941:
915:. Retrieved
906:
897:
885:. Retrieved
876:
867:
855:. Retrieved
846:
836:
824:. Retrieved
815:
805:
793:. Retrieved
784:
759:. Retrieved
750:
740:
715:
711:
705:
680:
676:
669:
642:
638:
628:
617:. Retrieved
582:(1): 32–43.
579:
575:
562:
527:
496:
493:Side effects
476:
469:
445:
433:
423:
390:
386:
385:
374:
368:
29:
1249:from market
1213:Prenylamine
1178:Hexobendine
1138:Carbocromen
1117:Flosequinan
1098:Trolnitrate
1094:Tenitramine
1075:Molsidomine
1070:Linsidomine
857:17 February
761:17 February
639:Circulation
597:11379/60663
538:Paresthesia
466:Controversy
407:homeostasis
395:recombinant
295: g·mol
124:124584-08-3
109:Identifiers
1280:Categories
1228:Vericiguat
1208:Pimobendan
1203:Oxyfedrine
1198:Nicorandil
1193:Nesiritide
1173:Heptaminol
1168:Gapicomine
1148:Cloridarol
1080:Nicorandil
917:2012-12-18
619:2019-04-05
554:References
543:Somnolence
387:Nesiritide
300:3D model (
284:Molar mass
209:P7WI8UL647
180:ChemSpider
115:CAS Number
34:Nesiritide
1259:Phase III
1247:Withdrawn
1218:Serelaxin
1183:Imolamine
1163:Etafenone
1143:Cinepazet
1108:Quinolone
533:Confusion
393:, is the
73:Routes of
65:Monograph
59:Drugs.com
1286:Peptides
1223:Trapidil
1158:Efloxate
1025:used in
972:12921256
911:Archived
881:Archived
851:Archived
820:Archived
789:Archived
755:Archived
732:17003394
697:15840865
661:15781736
610:Archived
606:21732835
508:Headache
391:Natrecor
377:(verify)
189:24603113
160:DrugBank
149:16134381
85:ATC code
18:Natrecor
1153:Dilazep
963:3746126
887:31 July
456:elderly
245:Formula
169:DB04899
135:PubChem
101:)
95: (
93:C01DX19
79:IV only
1242:WHO-EM
1126:Others
970:
960:
826:17 May
816:Forbes
795:4 June
730:
695:
659:
604:
548:Tremor
513:Nausea
405:fluid
326:SMILES
220:ChEMBL
613:(PDF)
572:(PDF)
452:bolus
346:InChI
302:JSmol
1031:C01D
968:PMID
889:2018
859:2017
828:2022
797:2019
763:2017
728:PMID
712:JAMA
693:PMID
677:JAMA
657:PMID
602:PMID
200:UNII
55:AHFS
958:PMC
950:doi
720:doi
716:296
685:doi
681:293
647:doi
643:111
592:hdl
584:doi
580:365
293:.07
291:464
259:244
253:143
139:CID
98:WHO
1282::
1255::
966:.
956:.
946:23
944:.
940:.
909:.
905:.
875:.
849:.
845:.
818:.
814:.
787:.
783:.
771:^
753:.
749:.
726:.
714:.
691:.
679:.
655:.
641:.
637:.
608:.
600:.
590:.
578:.
574:.
460:mg
271:42
265:50
1056:#
1050:#
1033:)
1029:(
1015:e
1008:t
1001:v
974:.
952::
920:.
891:.
830:.
734:.
722::
699:.
687::
663:.
649::
622:.
594::
586::
304:)
289:3
277:4
274:S
268:O
262:N
256:H
250:C
57:/
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
